NO312814B1 - Anvendelse av melatonin ved fremstilling av et medikament for behandling av pasienter som lider av medikamentavhengighet - Google Patents
Anvendelse av melatonin ved fremstilling av et medikament for behandling av pasienter som lider av medikamentavhengighet Download PDFInfo
- Publication number
- NO312814B1 NO312814B1 NO19973531A NO973531A NO312814B1 NO 312814 B1 NO312814 B1 NO 312814B1 NO 19973531 A NO19973531 A NO 19973531A NO 973531 A NO973531 A NO 973531A NO 312814 B1 NO312814 B1 NO 312814B1
- Authority
- NO
- Norway
- Prior art keywords
- melatonin
- drug
- treatment
- benzodiazepine
- patient
- Prior art date
Links
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims abstract description 117
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 229960003987 melatonin Drugs 0.000 title claims abstract description 115
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 229940079593 drug Drugs 0.000 title claims abstract description 69
- 238000011282 treatment Methods 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 208000011117 substance-related disease Diseases 0.000 title description 2
- 206010013663 drug dependence Diseases 0.000 title 1
- 229940049706 benzodiazepine Drugs 0.000 claims abstract description 83
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims abstract description 61
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 230000001419 dependent effect Effects 0.000 claims abstract description 14
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- 150000001557 benzodiazepines Chemical class 0.000 claims description 22
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 14
- 229960003529 diazepam Drugs 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 206010012335 Dependence Diseases 0.000 claims description 10
- 239000003607 modifier Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 102000001419 Melatonin receptor Human genes 0.000 claims description 9
- 108050009605 Melatonin receptor Proteins 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 7
- 229960002200 flunitrazepam Drugs 0.000 claims description 6
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 claims description 6
- 229960004535 oxazepam Drugs 0.000 claims description 6
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 claims description 5
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 229960004391 lorazepam Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- -1 Chlorazepat Chemical compound 0.000 claims description 3
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 claims description 3
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 claims description 3
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004538 alprazolam Drugs 0.000 claims description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003528 flurazepam Drugs 0.000 claims description 3
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 3
- 229960002158 halazepam Drugs 0.000 claims description 3
- 229960004856 prazepam Drugs 0.000 claims description 3
- 229960003188 temazepam Drugs 0.000 claims description 3
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003386 triazolam Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 25
- 230000007958 sleep Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- QQEILXDLZRLTME-UHFFFAOYSA-N 6-sulfatoxymelatonin Chemical compound C1=C(OS(O)(=O)=O)C(OC)=CC2=C1NC=C2CCNC(C)=O QQEILXDLZRLTME-UHFFFAOYSA-N 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000003860 sleep quality Effects 0.000 description 4
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000008454 sleep-wake cycle Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000919956 Guzmania lingulata Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/381,535 US6469044B1 (en) | 1995-02-01 | 1995-02-01 | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| EP95303853A EP0724878B1 (en) | 1995-02-01 | 1995-06-06 | Use of melatonin for treating patients suffering from drug dependencies |
| PCT/IB1996/000082 WO1996023496A1 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treating patients suffering from drug addiction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973531D0 NO973531D0 (no) | 1997-07-31 |
| NO973531L NO973531L (no) | 1997-09-30 |
| NO312814B1 true NO312814B1 (no) | 2002-07-08 |
Family
ID=26140195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973531A NO312814B1 (no) | 1995-02-01 | 1997-07-31 | Anvendelse av melatonin ved fremstilling av et medikament for behandling av pasienter som lider av medikamentavhengighet |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JP4516159B2 (et) |
| CN (1) | CN1083263C (et) |
| AT (1) | AT408188B (et) |
| AU (1) | AU695366B2 (et) |
| BG (1) | BG62876B1 (et) |
| BR (1) | BR9607169A (et) |
| CZ (1) | CZ291349B6 (et) |
| DK (1) | DK176081B1 (et) |
| EE (1) | EE03384B1 (et) |
| FI (1) | FI119586B (et) |
| IS (1) | IS1980B (et) |
| LU (1) | LU90118B1 (et) |
| LV (1) | LV11940B (et) |
| MD (1) | MD1716C2 (et) |
| NO (1) | NO312814B1 (et) |
| NZ (1) | NZ298878A (et) |
| PL (1) | PL183148B1 (et) |
| SI (1) | SI9620022A (et) |
| SK (1) | SK284521B6 (et) |
| TR (1) | TR199700723T1 (et) |
| TW (1) | TW483757B (et) |
| WO (1) | WO1996023496A1 (et) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0016918A (pt) | 2000-01-05 | 2004-03-23 | Neurim Pharma 1991 | Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| RU2631602C2 (ru) | 2012-01-26 | 2017-09-25 | Ванда Фармасьютиклз Инк. | Лечение нарушений циркадного ритма |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| AU2013361459A1 (en) | 2012-12-18 | 2015-07-02 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| EP3337462B1 (en) * | 2016-10-31 | 2020-09-30 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000073I1 (de) * | 1991-05-09 | 2008-01-31 | Neurim Pharma 1991 | Melatonin enthaltene Arzneimittel |
| IT1251544B (it) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico |
-
1996
- 1996-01-29 BR BR9607169A patent/BR9607169A/pt not_active Application Discontinuation
- 1996-01-29 WO PCT/IB1996/000082 patent/WO1996023496A1/en active IP Right Grant
- 1996-01-29 AU AU44574/96A patent/AU695366B2/en not_active Expired
- 1996-01-29 JP JP52338596A patent/JP4516159B2/ja not_active Expired - Lifetime
- 1996-01-29 SI SI9620022A patent/SI9620022A/sl not_active IP Right Cessation
- 1996-01-29 CZ CZ19972405A patent/CZ291349B6/cs not_active IP Right Cessation
- 1996-01-29 NZ NZ298878A patent/NZ298878A/xx not_active IP Right Cessation
- 1996-01-29 EE EE9700166A patent/EE03384B1/et not_active IP Right Cessation
- 1996-01-29 MD MD97-0254A patent/MD1716C2/ro not_active IP Right Cessation
- 1996-01-29 PL PL96321630A patent/PL183148B1/pl unknown
- 1996-01-29 TR TR97/00723T patent/TR199700723T1/xx unknown
- 1996-01-29 CN CN96191750A patent/CN1083263C/zh not_active Expired - Lifetime
- 1996-01-29 SK SK1030-97A patent/SK284521B6/sk unknown
- 1996-01-29 AT AT0901396A patent/AT408188B/de not_active IP Right Cessation
- 1996-04-12 TW TW085104319A patent/TW483757B/zh not_active IP Right Cessation
-
1997
- 1997-07-24 LV LVP-97-144A patent/LV11940B/en unknown
- 1997-07-25 IS IS4532A patent/IS1980B/is unknown
- 1997-07-30 BG BG101803A patent/BG62876B1/bg unknown
- 1997-07-30 DK DK199700896A patent/DK176081B1/da not_active IP Right Cessation
- 1997-07-31 FI FI973185A patent/FI119586B/fi not_active IP Right Cessation
- 1997-07-31 NO NO19973531A patent/NO312814B1/no not_active IP Right Cessation
- 1997-08-01 LU LU90118A patent/LU90118B1/fr active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jehan et al. | Sleep disorders in postmenopausal women | |
| Schulz et al. | The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study | |
| Askenasy | Sleep disturbances in Parkinsonism | |
| AU780013B2 (en) | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists | |
| EP0724878B1 (en) | Use of melatonin for treating patients suffering from drug dependencies | |
| Walsh et al. | Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia | |
| Pierce et al. | Optimal melatonin dose in older adults: A clinical review of the literature | |
| DK2644198T3 (en) | ANTIANXIETY AND SLEEP DISORDER IMPROVING USE OF ALBIFLORIN | |
| NO312814B1 (no) | Anvendelse av melatonin ved fremstilling av et medikament for behandling av pasienter som lider av medikamentavhengighet | |
| EP2138174A1 (en) | Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management | |
| Brambilla et al. | Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa | |
| CA2211839C (en) | Use of melatonin for treating patients suffering from drug addiction | |
| Hajak et al. | Clinical management of patients with insomnia: the role of zopiclone | |
| MXPA97005856A (en) | Use of melatonine in the manufacture of unmedicament to deal with addiction to dro | |
| e Silva et al. | Midazolam and triazolam in out‐patients: a double‐blind comparison of hypnotic efficacy. | |
| Mendelson | DRUGS WITH HYPNOTIC PROPERTIES | |
| Conroy et al. | Sleep and substance use and abuse | |
| Wurtman | Ramelteon: a melatonin receptor agonist | |
| Zucconi | Do dopaminergic agents increase the daytime sleep propensity?: Article reviewed: Effect of ropinirole on sleep onset. A randomized, placebo-controlled study in healthy volunteers | |
| Medrano | Anxiolytics and Hypnotics | |
| Prodhan et al. | Melatonin and sleep disturbances in Alzheimer’s | |
| CN108135953A (zh) | 新的改善睡眠的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |